A clinical evaluation of the comparable efficacy of hyaluronic acid‐based foam and ceramide‐containing emulsion cream in the treatment of mild‐to‐moderate atopic dermatitis
SummaryBackground A variety of prescription devices have been developed to improve barrier function in persons with atopic dermatitis. These products are based primarily on the use of occlusive agents to decrease transepidermal water loss, creating an environment for optimal healing.Aim ...
SummaryBackground A variety of prescription devices have been developed to improve barrier function in persons with atopic dermatitis. These products are based primarily on the use of occlusive agents to decrease transepidermal water loss, creating an environment for optimal healing.Aim A newly developed hyaluronic acid based, pH neutral foam technology formulated to maximize humectancy and normalize transepidermal waster loss was evaluated for its ability to optimize barrier function while minimizing unnecessary irritation.Methods This double blind split body study enrolled 20 subjects with mild to moderate symmetrical atopic dermatitis involving body surface area greater than or equal to 10% using the arms or the legs as the target site. Subjects were randomized to apply the hyaluronic acid based emollient foam or the reference ceramide‐containing emulsion cream to one side of the body with the other test product applied to the opposite side. Subject and investigator ratings were made for erythema, scaling, lichenification, excoriation, itching, stinging, and burning at baseline, week 2, and week 4.Results Both formulations achieved statistically significant improvement in all clinical signs and symptoms of atopic dermatitis by week 4, however the hyaluronic acid foam achieved statistically significant improvement in overall eczema severity by week 2, whereas the ceramide‐containing emulsion cream did not. The subject’s preference statistically significantly favored the foam in terms of ability to spread, moisturize, ease of use, and lack of odor. In addition, the foam was preferred for effectiveness and ability to soothe.Conclusion A prescription hyaluronic acid based foam device offers an aesthetic formulation with excellent efficacy in patients requiring an environment for barrier repair with mild to moderate atopic dermatitis.
SummaryBackground A variety of prescription devices have been developed to improve barrier function in persons with atopic dermatitis. These products are based primarily on the use of occlusive agents to decrease transepidermal water loss, creating an environment for optimal healing.Aim A newly developed hyaluronic acid based, pH neutral foam technology formulated to maximize humectancy and normalize transepidermal waster loss was evaluated for its ability to optimize barrier function while minimizing unnecessary irritation.Methods This double blind split body study enrolled 20 subjects with mild to moderate symmetrical atopic dermatitis involving body surface area greater than or equal to 10% using the arms or the legs as the target site. Subjects were randomized to apply the hyaluronic acid based emollient foam or the reference ceramide‐containing emulsion cream to one side of the body with the other test product applied to the opposite side. Subject and investigator ratings were made for erythema, scaling, lichenification, excoriation, itching, stinging, and burning at baseline, week 2, and week 4.Results Both formulations achieved statistically significant improvement in all clinical signs and symptoms of atopic dermatitis by week 4, however the hyaluronic acid foam achieved statistically significant improvement in overall eczema severity by week 2, whereas the ceramide‐containing emulsion cream did not. The subject’s preference statistically significantly favored the foam in terms of ability to spread, moisturize, ease of use, and lack of odor. In addition, the foam was preferred for effectiveness and ability to soothe.Conclusion A prescription hyaluronic acid based foam device offers an aesthetic formulation with excellent efficacy in patients requiring an environment for barrier repair with mild to moderate atopic dermatitis.
Krejci-Manwaring Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis J Am Acad Deramtol 2007 10.1016/j.jaad.2006.05.073 56 2 211
Hanifin Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines” J Am Acad Dermatol 2004 10.1016/j.jaad.2003.08.003 50 3 391
Santor Comparisons of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis J Am Acad Deramtol 2003 10.1067/mjd.2003.105 48 3 352
Maytin Hyaluronan participates in the epidermal response to disruption of the permeability barrier in vivo Am J Pathol 2004 10.1016/S0002-9440(10)63391-3 165 1331
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.